SURAKSHA DIAGNOSTIC LTD
Latest filings
- Board comments on Rs. 2,360 NSE fine for delayed shareholding pattern filing · Regulatory & Legal
- Ms. Shreya Arora appointed as Company Secretary and Compliance Officer · Management Changes
- Routine SEBI compliance certificate on dematerialisation for Q2 FY27 · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Operates a network of 68 diagnostic centres providing pathology and radiology testing services, primarily in West Bengal with newer hubs in Bihar, Tripura, Jharkhand and Assam. In FY26, the network served 1.37 million patients and conducted 8.16 million tests, generating revenue per patient of INR 2,264. The revenue mix is 49% pathology, 44% radiology and 7% integrated doctor consultancy, close to the industry-wide ~55:45 pathology-to-radiology split. Mature centres (over 2 years old) generate 36-37% EBITDA margins while newer centres are at -5.5% during ramp-up, blending to an FY26 EBITDA margin of 31.75%. A genomics vertical (Suraksha Genomics) has been launched using the Genexus NGS platform for 48-72 hour oncology turnaround, running at INR 35 lakh/month, and a 63% stake in fertility chain Fetomat Wellness was acquired in April 2025. Employee costs (17.2% of revenue) and other operating expenses (40.4% of revenue) are the largest cost lines, with capex at 21.7% of revenue supporting the hub-and-spoke rollout toward 100 centres by FY28.
Scorecard
Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SURAKSHA DIAGNOSTIC LTD's filed financials and exchange disclosures
What does SURAKSHA DIAGNOSTIC LTD do?
SURAKSHA DIAGNOSTIC LTD is a Healthcare Services company listed on NSE and BSE, trading under the symbol SURAKSHA.
Is SURAKSHA DIAGNOSTIC LTD profitable?
Yes. Over the trailing twelve months SURAKSHA DIAGNOSTIC LTD reported a net profit of ₹35 Cr on revenue of ₹325 Cr.
Does SURAKSHA DIAGNOSTIC LTD pay a dividend?
Not in the latest reported year — SURAKSHA DIAGNOSTIC LTD's dividend payout for FY26 was nil.
Is SURAKSHA DIAGNOSTIC LTD debt-free?
On a net basis, yes. It reported borrowings of ₹1.73 Cr on its 31 Mar 2026 balance sheet, but holds ₹1.48 Cr more cash than debt.
Is SURAKSHA DIAGNOSTIC LTD expensive compared with its peers?
On trailing P/E, SURAKSHA DIAGNOSTIC LTD ranks 16 of 25 in Healthcare Service Provider — cheaper than 38% of them, against an industry median of 23.6×. This is a position, not a valuation judgement.
How much does the SURAKSHA DIAGNOSTIC LTD share price move in a day?
On a typical session SURAKSHA DIAGNOSTIC LTD moves 1.09% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track SURAKSHA DIAGNOSTIC LTD's announcements?
Every NSE and BSE filing by SURAKSHA DIAGNOSTIC LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.